Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to ...

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies Provided by GlobeNewswire Jul 3, 2025, 12:00:00 AM ...

The OBT-Boehringer partnership began in 2013 and has expanded through subsequent agreements in 2020 and 2022 to include additional programs. The collaboration has yielded multiple development-stage ...

Mumbai: Global pharma major Lupin Limited has launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in ...

Ipratropium bromide nasal solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, ...